These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 26728648)

  • 1. Efficacy and safety of a hydrocodone extended-release tablet formulated with abuse-deterrence technology in patients with moderate-to-severe chronic low back pain.
    Hale ME; Zimmerman TR; Eyal E; Malamut R
    J Opioid Manag; 2015; 11(6):507-18. PubMed ID: 26728648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Six-month, open-label study of hydrocodone extended release formulated with abuse-deterrence technology: Safety, maintenance of analgesia, and abuse potential.
    Hale ME; Ma Y; Malamut R
    J Opioid Manag; 2016; 12(2):139-47. PubMed ID: 27194199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Twelve-month, open-label assessment of long-term safety and abuse potential of hydrocodone extended-release formulated with abuse-deterrence technology in patients with chronic pain.
    Hale ME; Zimmerman TR; Ma Y; Malamut R
    J Opioid Manag; 2015; 11(5):425-34. PubMed ID: 26535970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-entity hydrocodone extended-release capsules in opioid-tolerant subjects with moderate-to-severe chronic low back pain: a randomized double-blind, placebo-controlled study.
    Rauck RL; Nalamachu S; Wild JE; Walker GS; Robinson CY; Davis CS; Farr SJ
    Pain Med; 2014 Jun; 15(6):975-85. PubMed ID: 24517082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability of Biphasic-Release Hydrocodone Bitartrate/Acetaminophen Tablets (MNK-155): A Phase III, Multicenter, Open-Label Study in Patients With Osteoarthritis or Chronic Low Back Pain.
    Zheng Y; Kostenbader K; Barrett T; Hisaw E; Giuliani MJ; Chen Y; Young JL
    Clin Ther; 2015 Jun; 37(6):1235-47. PubMed ID: 25913923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 12-Month safety and effectiveness of once-daily hydrocodone tablets formulated with abuse-deterrent properties in patients with moderate to severe chronic pain.
    Wen W; Taber L; Lynch SY; He E; Ripa S
    J Opioid Manag; 2015; 11(4):339-56. PubMed ID: 26312961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, double-blind, placebo-controlled study of the efficacy and safety of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen tablets for acute postoperative pain.
    Singla N; Margulis R; Kostenbader K; Zheng Y; Barrett T; Giuliani MJ; Chen Y; Young JL
    Phys Sportsmed; 2015 May; 43(2):126-37. PubMed ID: 25796986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Quality of Life, Functioning, Disability, and Work/School Productivity Following Treatment with an Extended-Release Hydrocodone Tablet Formulated with Abuse-Deterrence Technology: A 12-month Open-label Study in Patients with Chronic Pain.
    Hale ME; Zimmerman TR; Ma Y; Malamut R
    Pain Pract; 2017 Feb; 17(2):229-238. PubMed ID: 26857424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety and effectiveness of once-daily, single-entity, extended-release hydrocodone over 76 weeks of an open-label study in patients with chronic noncancer and nonneuropathic pain.
    Taber L; Lynch SY; He E; Ripa SR
    Postgrad Med; 2016 Jan; 128(1):23-33. PubMed ID: 26681111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of the extended-release tramadol hydrochloride/acetaminophen fixed-dose combination tablet for the treatment of chronic low back pain.
    Lee JH; Lee CS;
    Clin Ther; 2013 Nov; 35(11):1830-40. PubMed ID: 24183364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between change in pain intensity and functional outcomes in patients with chronic pain receiving twice daily extended-release hydrocodone bitartrate.
    Argoff C; Arnstein P; Stanos S; Robinson CY; Galer BS; Gould E; Gammaitoni A
    J Opioid Manag; 2015; 11(5):417-24. PubMed ID: 26535969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of a hydrocodone extended-release tablet formulated with abuse-deterrence technology for the treatment of moderate-to-severe chronic pain in patients with osteoarthritis or low back pain.
    Hale ME; Laudadio C; Yang R; Narayana A; Malamut R
    J Pain Res; 2015; 8():623-36. PubMed ID: 26396543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Analysis of Rescue Medication Utilization from a 3-Month, Randomized, Double-Blind, Placebo-Controlled Study in Patients with Chronic Low Back Pain Treated with Single-Entity, Twice-Daily, Extended-Release Hydrocodone.
    Nalamachu S; deLeon-Casasola OA; Robinson CY; Galer BS; Gould E; Gammaitoni A
    Pain Med; 2015 Dec; 16(12):2338-43. PubMed ID: 26301791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of once-daily, extended-release hydrocodone in individuals previously receiving hydrocodone/acetaminophen combination therapy for chronic pain.
    Bartoli A; Michna E; He E; Wen W
    Postgrad Med; 2015 Jan; 127(1):5-12. PubMed ID: 25526227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers.
    Darwish M; Yang R; Tracewell W; Robertson P; Bond M
    Clin Ther; 2015 Feb; 37(2):390-401. PubMed ID: 25542074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study.
    Hale ME; Ahdieh H; Ma T; Rauck R;
    J Pain; 2007 Feb; 8(2):175-84. PubMed ID: 17145204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of single-entity, once-daily hydrocodone tablets in patients with uncontrolled moderate to severe chronic low back pain.
    Wen W; Sitar S; Lynch SY; He E; Ripa SR
    Expert Opin Pharmacother; 2015; 16(11):1593-606. PubMed ID: 26111544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users.
    Bond M; Schoedel KA; Rabinovich-Guilatt L; Gasior M; Tracewell W; Malamut R; Ma Y; Webster LR
    Pain Med; 2018 Aug; 19(8):1597-1612. PubMed ID: 29016880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of flupirtine modified release for the management of moderate to severe chronic low back pain: results of SUPREME, a prospective randomized, double-blind, placebo- and active-controlled parallel-group phase IV study.
    Uberall MA; Mueller-Schwefe GH; Terhaag B
    Curr Med Res Opin; 2012 Oct; 28(10):1617-34. PubMed ID: 22970658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use.
    Peniston JH; Gould E
    Clin Ther; 2009 Feb; 31(2):347-59. PubMed ID: 19302907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.